Michael Weintraub - Phreesia Independent Chairman of the Board
| PHR Stock | USD 21.03 0.73 3.60% |
Chairman
Mr. Michael Weintraub is Chairman of the Board of Phreesia, Inc. Michael was most recently Managing Partner of Optum Ventures, focused on digital health innovation. Previously, he was CoFounder and CEO of Humedica, a pioneer and leader in the field of population health management and big data. Humedica was acquired by UnitedHealth Group in 2013, and Michael broadened his role within UHG as President and CEO of Optum Analytics. Prior to launching Humedica, he served as Senior Managing Director at Leerink Partners, a leading healthcare investment bank. Michael also served as President and CEO of PHARMetrics, a health care informatics company, which was successfully sold to IMS Health in 2005. He serves as Founding Chairman of the Board of Phreesia, the nations leading patient intake management company. Michael is an Advisory Board member of the Innovation and Digital Health Accelerator at Boston Childrens Hospital. He serves as a mentor and speaker at the Harvard Innovation Lab, a unique collaboration and education space designed to foster entrepreneurship. Michael is a member of the Board of Directors of Juvenile Diabetes Research Foundation, New England Chapter as well as The College Diabetes Network, whose mission is to empower and improve the lives of students living with Type 1 diabetes through peer support and access to information and resources. He received his MBA from Harvard Business School and his bachelors degree in Economics from Brandeis University. since 2005.
| Age | 61 |
| Tenure | 19 years |
| Professional Marks | MBA |
| Address | 1521 Concord Pike, Wilmington, DE, United States, 19803 |
| Phone | 888 654 7473 |
| Web | https://www.phreesia.com |
Michael Weintraub Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Weintraub against Phreesia stock is an integral part of due diligence when investing in Phreesia. Michael Weintraub insider activity provides valuable insight into whether Phreesia is net buyers or sellers over its current business cycle. Note, Phreesia insiders must abide by specific rules, including filing SEC forms every time they buy or sell Phreesia'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Weintraub over a year ago Acquisition by Michael Weintraub of 6051 shares of Phreesia subject to Rule 16b-3 |
Phreesia Management Efficiency
The company has Return on Asset of (0.1664) % which means that on every $100 spent on assets, it lost $0.1664. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4026) %, meaning that it generated no profit with money invested by stockholders. Phreesia's management efficiency ratios could be used to measure how well Phreesia manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/02/2024, Return On Tangible Assets is likely to drop to -0.66. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Phreesia's Net Tangible Assets are relatively stable compared to the past year. As of 12/02/2024, Non Current Assets Total is likely to grow to about 183.4 M, while Non Currrent Assets Other are likely to drop slightly above 3.3 M.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Frank Williams | Evolent Health | 58 | |
| Robert Frist | HealthStream | 57 | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.17 |
Phreesia Leadership Team
Elected by the shareholders, the Phreesia's board of directors comprises two types of representatives: Phreesia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phreesia. The board's role is to monitor Phreesia's management team and ensure that shareholders' interests are well served. Phreesia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phreesia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Davidoff, Senior Vice President - Marketing and Business Development | ||
| Evan Roberts, Co-Founder, Vice President - Customer Solutions | ||
| Scott Perricelli, Independent Director | ||
| Charles Kallenbach, General Counsel, Secretary | ||
| Chaim Indig, Chief Executive Officer, Board Member | ||
| Balaji Gandhi, Senior Vice President - Investor Relations | ||
| Mark Smith, Independent Director | ||
| Lainie Goldstein, Independent Director | ||
| Hilary Hatch, Chief Officer | ||
| Ashwin Uttamchandani, Vice Operations | ||
| Daniel Nathan, Chief Technology Officer | ||
| Kharen Hauck, Vice Marketing | ||
| Ramin Sayar, Director | ||
| Jack Callahan, Chief Officer | ||
| Maureen McKinney, Vice Communications | ||
| Allison JD, General Secretary | ||
| Thomas Altier, Chief Financial Officer | ||
| Cheryl Pegus, Independent Director | ||
| Edward Cahill, Independent Director | ||
| Janet Gunzburg, Principal VP | ||
| David Linetsky, Senior Vice President - Life Sciences | ||
| Randy Rasmussen, Chief Accounting Officer | ||
| Gillian Munson, Independent Director | ||
| Amy VanDuyn, Senior Vice President - Human Resources | ||
| Dusty Lieb, Director | ||
| Yvonne Hui, VP Officer | ||
| Allison Hoffman, General Counsel, Secretary | ||
| Michael Weintraub, Independent Chairman of the Board |
Phreesia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phreesia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 1.15 B | ||||
| Shares Outstanding | 57.77 M | ||||
| Shares Owned By Insiders | 4.62 % | ||||
| Shares Owned By Institutions | 97.95 % | ||||
| Number Of Shares Shorted | 2.93 M | ||||
| Price To Earning | 27.08 X |
Pair Trading with Phreesia
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phreesia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phreesia will appreciate offsetting losses from the drop in the long position's value.Moving against Phreesia Stock
| 0.83 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.78 | VMD | Viemed Healthcare | PairCorr |
| 0.73 | VRNA | Verona Pharma PLC | PairCorr |
| 0.73 | ETON | Eton Pharmaceuticals | PairCorr |
| 0.65 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Phreesia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phreesia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phreesia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phreesia to buy it.
The correlation of Phreesia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phreesia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phreesia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phreesia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Phreesia Stock Analysis
When running Phreesia's price analysis, check to measure Phreesia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phreesia is operating at the current time. Most of Phreesia's value examination focuses on studying past and present price action to predict the probability of Phreesia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phreesia's price. Additionally, you may evaluate how the addition of Phreesia to your portfolios can decrease your overall portfolio volatility.